Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)

BIOLOGICAL2 trials

Sponsors

Seqirus

Conditions

InfluenzaInfluenza Virus

Phase 3

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

CompletedNCT01964989

SeqirusInfluenza Virus

Start: 2013-11-30End: 2016-08-31Updated: 2023-03-27

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05

CompletedNCT02255409

SeqirusInfluenza

Start: 2014-10-31End: 2016-01-31Updated: 2023-03-15

Related Papers

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial

The Pediatric Infectious Disease Journal2020-05-148 citations

Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.

2018-04-0649 citations